Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
PW Medtech Group Ltd. ( (HK:1358) ) has shared an update.
Non-wholly owned subsidiary Sichuan Ruijian Medical, a blood purification device specialist listed on China’s NEEQ, reported strong audited 2025 results, with revenue rising 27.22% to RMB614.6 million and profit for the year up 14.71% to RMB146.1 million. Total assets climbed to RMB1.13 billion and equity to RMB1.03 billion, underscoring solid balance sheet growth that will feed into PW Medtech’s consolidated accounts, though the parent cautioned investors that these figures relate solely to the subsidiary and should be considered carefully when trading its shares.
The most recent analyst rating on (HK:1358) stock is a Buy with a HK$1.50 price target. To see the full list of analyst forecasts on PW Medtech Group Ltd. stock, see the HK:1358 Stock Forecast page.
More about PW Medtech Group Ltd.
PW Medtech Group Ltd., incorporated in the Cayman Islands, is an investment holding company focused on medical devices in mainland China. Through its subsidiaries, it engages in R&D, manufacturing and sales of advanced infusion sets, intravenous cannula products, insulin needles, blood purification medical devices, and animal-derived regenerative biomaterials and human tissue repair alternatives in the PRC market.
Average Trading Volume: 438,106
Technical Sentiment Signal: Buy
Current Market Cap: HK$1.96B
Learn more about 1358 stock on TipRanks’ Stock Analysis page.